Antibody data
- Antibody Data
- Antigen structure
- References [15]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN255959 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Syndecan 1 (SDC1) antibody
- Antibody type
- Monoclonal
- Description
- Protein G purified
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- B-A38
- Vial size
- 0.1 mg
- Storage
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles
Submitted references A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Loss of cell invasiveness through PKC-mediated syndecan-1 downregulation in melanoma cells under anchorage independency.
CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.
Presence of Porphyromonas gingivalis and plasma cell dominance in gingival tissues with periodontitis.
Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis.
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature.
Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.
Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.
Syndecan-1 and tenascin expression in cystic tumors of the pancreas.
High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes.
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation.
Sharpe B, Alghezi DA, Cattermole C, Beresford M, Bowen R, Mitchard J, Chalmers AD
The Prostate 2017 May;77(13):1312-1324
The Prostate 2017 May;77(13):1312-1324
Loss of cell invasiveness through PKC-mediated syndecan-1 downregulation in melanoma cells under anchorage independency.
Wang C, Tseng T, Jhang Y, Tseng J, Hsieh C, Wu WG, Lee S
Experimental dermatology 2014 Nov;23(11):843-9
Experimental dermatology 2014 Nov;23(11):843-9
CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
Chang H, Jiang N, Jiang H, Saha MN, Qi C, Xu W, Reece D
Haematologica 2010 Sep;95(9):1542-7
Haematologica 2010 Sep;95(9):1542-7
Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.
Beauvais DM, Rapraeger AC
Journal of cell science 2010 Nov 1;123(Pt 21):3796-807
Journal of cell science 2010 Nov 1;123(Pt 21):3796-807
Presence of Porphyromonas gingivalis and plasma cell dominance in gingival tissues with periodontitis.
Kim YC, Ko Y, Hong SD, Kim KY, Lee YH, Chae C, Choi Y
Oral diseases 2010 May;16(4):375-81
Oral diseases 2010 May;16(4):375-81
Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis.
Thaunat O, Patey N, Caligiuri G, Gautreau C, Mamani-Matsuda M, Mekki Y, Dieu-Nosjean MC, Eberl G, Ecochard R, Michel JB, Graff-Dubois S, Nicoletti A
Journal of immunology (Baltimore, Md. : 1950) 2010 Jul 1;185(1):717-28
Journal of immunology (Baltimore, Md. : 1950) 2010 Jul 1;185(1):717-28
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature.
Li K, Tipps AM, Wang HY
International journal of clinical and experimental pathology 2010 Jan 23;4(2):190-6
International journal of clinical and experimental pathology 2010 Jan 23;4(2):190-6
Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.
Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY
International journal of clinical and experimental pathology 2010 Apr 23;3(4):448-57
International journal of clinical and experimental pathology 2010 Apr 23;3(4):448-57
Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.
Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC
The Journal of experimental medicine 2009 Mar 16;206(3):691-705
The Journal of experimental medicine 2009 Mar 16;206(3):691-705
Syndecan-1 and tenascin expression in cystic tumors of the pancreas.
Kylänpää L, Hagström J, Lepistö A, Linjama T, Kärkkäinen P, Kiviluoto T, Haglund C
JOP : Journal of the pancreas 2009 Jul 6;10(4):378-82
JOP : Journal of the pancreas 2009 Jul 6;10(4):378-82
High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes.
Mahshid Y, Lisy MR, Wang X, Spanbroek R, Flygare J, Christensson B, Björkholm M, Sander B, Habenicht AJ, Claesson HE
BMC immunology 2009 Jan 9;10:2
BMC immunology 2009 Jan 9;10:2
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD
Blood 2007 Sep 15;110(6):2041-8
Blood 2007 Sep 15;110(6):2041-8
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG
Blood 2005 Feb 15;105(4):1660-8
Blood 2005 Feb 15;105(4):1660-8
Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A, Kajanti M, Heikkilä P, Jalkanen M, Joensuu H
British journal of cancer 1999 Feb;79(3-4):558-64
British journal of cancer 1999 Feb;79(3-4):558-64
Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation.
Borset M, Helseth E, Naume B, Waage A
British journal of haematology 1993 Nov;85(3):446-51
British journal of haematology 1993 Nov;85(3):446-51
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- FACS